Epilepsy Treatment

Epilepsy syndromes fall into two broad categories: generalized and partial (or localization-related) syndromes. In generalized epilepsies, the predominant type of seizures begins simultaneously in both cerebral hemispheres.

Epilepsy is one of the most common neurologic problems worldwide. Approximately 2 million people in the United States have epilepsy, and 3 percent of people in the general population will have epilepsy at some point in their lives. In recent years, important advances have been made in the diagnosis and treatment of seizure disorders. However, our understanding of the cellular and molecular mechanisms by which epilepsy develops, or epileptogenesis, is still incomplete.

Many forms of generalized epilepsy have a strong genetic component; in most, neurologic function is normal. In partial epilepsies, by contrast, seizures originate in one or more localized foci, although they can spread to involve the entire brain. Most partial epilepsies are believed to be the result of one or more central nervous system insults, but in many cases the nature of the insult is never identified.

RCT is using specific peptides, growth factors and neurotrophic factors that carry encoded information to a specific receptor on neurons. This creates a series of intercellular reactions within the neurons. The signals pass through the nucleus of the cell until they arrive to the DNA. These signals stimulate the DNA. When this process is complete the RNA reads the new information and creates a functional protein based on the needs of that particular neuron. This causes the neuron to start functioning normally again.

Neurological disorders can stem from an over abundance or deficiency of neurotrophic factors. The specific neurotrophic factors RCT is using have the ability to regulate the neurons and support normal brain function.

When there are not enough neurotrophic factors being produced, the treatment will stimulate the neurons to produce the necessary levels. When there are too many of these molecules, it will inhibit the production of these neurotrophic factors.

• Read published research on the importance of Neurotrophic Factor levels here.

• Read published research on one of the molecules (IGF2) used in RCT’s treatment.

* RCT is not disclosing the complete set of molecules used in each treatment, in order to protect the process until patents are finalized.

The Neurotrophic Factors are not drugs; they are molecules that reconstitute the Central and Peripheral Nervous System. These contain a peptide, growth factor or neurotrophic factor fraction obtained by chromatography (Proteins extracted with a chromatographic purity greater than 99%). The neurotrophic factors used by RCT are specifically for Epilepsy.

Peptide-based treatments have neurotrophic effects on neurons of the central nervous system, stimulating the development, survival and neuritic growth. This promotes neuroplasticity, neuronal maturation and it creates new electrical contacts, known as synaptogenesis, which have transcendent effects. The improvements obtained are permanent and there is no regression of the advancements obtained.

In addition, Fibroblast growth factors can have a stimulating effect on the glutamatergic or pyramidal neurons of the cerebral cortex and other regions of the central nervous system, promoting the survival, development and activity of these types of neurons. Specifically in the frontal, parietal and temporal regions of the cerebral cortex, since these areas are critical for cognitive processes (awareness, recognition, analysis, reasoning, imagination etc.)

The same has proven to be effective in improving the function in learning disorders, such as Dyslexia and Attention Deficit, Autism Spectrum Disorders, Asperger syndrome, Down Syndrome, Cerebral Palsy, and Neuro degenerative Diseases.